Sugi Predict

Sugi Predict / Compounds / SCHEMBL4877157

SCHEMBL4877157

SCHEMBL4877157

OB(O)c1cccc(OC(F)(F)F)c1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 2/20 0.42
▸ MPL P40238 1/20 0.41
▸ ORAI1 Q96D31 1/20 0.37
▸ ORAI2 Q96SN7 1/20 0.37
▸ ORAI3 Q9BRQ5 1/20 0.37
▸ LIPE Q05469 1/20 0.36
▸ KCNK3 O14649 3/20 0.35
▸ KCNK9 Q9NPC2 3/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ SCN9A Q15858 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ HTR2C P28335 1/20 0.33
▸ HTR2B P41595 1/20 0.33
▸ PDE2A O00408 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29957207 1.00 ENPP2 (0.42) ENPP2MPLORAI1ORAI2ORAI3
SCHEMBL29546330 0.83 PDE2A (0.37) ENPP2MPLPDE2A
SCHEMBL21543839 0.83 PDE2A (0.37) ENPP2MPLPDE2A
SCHEMBL264406 0.82 ENPP2 (0.57) ENPP2ORAI1ORAI2ORAI3LIPE
SCHEMBL29417492 0.82 ENPP2 (0.57) ENPP2ORAI1ORAI2ORAI3LIPE
SCHEMBL29956867 0.81 ENPP2 (0.42) ENPP2ORAI1ORAI2ORAI3LIPE
SCHEMBL29951241 0.81 ENPP2 (0.42) ENPP2ORAI1ORAI2ORAI3LIPE
SCHEMBL29955371 0.80 ENPP2 (0.41) ENPP2ORAI1ORAI2ORAI3LIPE
SCHEMBL2446918 0.80 ENPP2 (0.41) ENPP2ORAI1ORAI2ORAI3LIPE
SCHEMBL29953300 0.80 ENPP2 (0.41) ENPP2ORAI1ORAI2ORAI3LIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163068-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2025-05-22 — — US disclosed
EP-4397308-A2 COMPOUNDS AND THEIR METHODS OFUSE Praxis Precision Medicines, Inc. (US) 2024-07-10 — — EP disclosed
CN-113913193-B Liquid crystal compound having negative dielectric anisotropy, liquid crystal composition, and liquid crystal display device 烟台显华科技集团股份有限公司 2024-05-17 — — CN disclosed
EP-3548033-B1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2024-04-10 — — EP disclosed
US-20230364079-A1 COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) 2023-11-16 — — US disclosed
WO-2023207949-A1 FUSED RING COMPOUND AND USE THEREOF 中国科学院上海药物研究所 2023-11-02 — — WO disclosed
CN-116947713-A Ring-merging compound and application thereof 中国科学院上海药物研究所 2023-10-27 — — CN disclosed
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-10-12 — — US disclosed
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-10-12 — — US disclosed
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-10-12 — — US disclosed
WO-2023134598-A1 POLYMERISABLE COMPOUND, COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE 烟台显华科技集团股份有限公司 2023-07-20 — — WO disclosed
EP-4186906-A1 COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) 2023-05-31 — — EP disclosed
US-11629146-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity PRAXIS PRECISION MEDICINES, INC. (US) 2023-04-18 — — US disclosed
CN-114394953-A Polymerizable compound, composition, and liquid crystal display device 烟台显华科技集团股份有限公司 2022-04-26 — — CN disclosed
CN-113913193-A Liquid crystal compound with negative dielectric anisotropy, liquid crystal composition and liquid crystal display device 烟台显华化工科技有限公司 2022-01-11 — — CN disclosed
US-20210188852-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2021-06-24 — — US disclosed
US-20210188852-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2021-06-24 — — US disclosed
EP-3548033-A1 COMPOUNDS AND THEIR METHODS OF USE Praxis Precision Medicines, Inc. (US) 2019-10-09 — — EP disclosed
WO-2018098499-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 — — WO disclosed
US-20080076771-A1 Thrombopoietin Receptor Agonists REITER LAWRENCE A 2008-03-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11629146-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity SCN1A, SCN5A, SCN3A ENPP2 784/4885MPL 4019/4885ORAI1 203/4885
US-20210188852-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B ENPP2 384/4885MPL 4276/4885ORAI1 248/4885
US-20250163068-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B ENPP2 384/4885MPL 4276/4885ORAI1 248/4885
US-20080076771-A1 Thrombopoietin Receptor Agonists MPL, THPO, TBXA2R ENPP2 280/4885MPL 1/4885ORAI1 3789/4885
US-20230364079-A1 COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF BTK, WEE2, WEE1 ENPP2 3545/4885MPL 916/4885ORAI1 2548/4885
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B ENPP2 384/4885MPL 4276/4885ORAI1 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.